Bridging dolutegravir clinical viral response across doses and formulations using model-based exposure-response analysis in pediatrics
AIDS. 2024 May 20. doi: 10.1097/QAD.0000000000003929. Online ahead of print. ABSTRACT OBJECTIVE: Dolutegravir (DTG) is a once-daily HIV-1 integrase inhibitor approved for the treatment of …